Core Viewpoint - Tianyi Medical (301097) experienced a slight decline in stock price, closing at 56.22 yuan on February 3, 2026, with a trading volume of 14,600 hands and a total transaction amount of 81.14 million yuan [1]. Group 1: Stock Performance - On February 3, 2026, the stock saw a net inflow of main funds amounting to 67.67 thousand yuan, representing 0.83% of the total transaction amount [1]. - Retail investors contributed a net inflow of 485.18 thousand yuan, accounting for 5.98% of the total transaction amount, while speculative funds experienced a net outflow of 552.86 thousand yuan, which is 6.81% of the total transaction amount [1]. Group 2: Financing and Margin Information - On the same day, the financing buy amounted to 920.57 thousand yuan, while financing repayment was 971.33 thousand yuan, resulting in a net repayment of 50.75 thousand yuan [2]. - The margin trading balance stood at 55.43 million yuan, with no shares sold or repaid in the securities lending segment [2]. Group 3: Financial Performance - For the first three quarters of 2025, Tianyi Medical reported a main revenue of 387 million yuan, reflecting a year-on-year increase of 24.14% [3]. - The net profit attributable to shareholders reached 20.09 million yuan, up 216.81% year-on-year, while the net profit excluding non-recurring items was 8.41 million yuan, showing a significant increase of 762.11% [3]. - In Q3 2025 alone, the company achieved a main revenue of 160 million yuan, a 48.03% increase year-on-year, and a net profit of 10.61 million yuan, which is a 227.86% increase year-on-year [3]. - The company's debt ratio is reported at 42.92%, with an investment loss of 7.25 million yuan and financial expenses of 767.7 thousand yuan, while the gross profit margin is at 38.39% [3]. Group 4: Analyst Ratings - In the last 90 days, one institution has issued a buy rating for Tianyi Medical [4].
天益医疗（301097）2月3日主力资金净买入67.67万元